171 related articles for article (PubMed ID: 29280500)
21. Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview.
Kølbæk P; Dines D; Holm T; Blicher AB; Sørensen RD; O'Leary KM; Feller SG; Buus CW; Nielsen CM; Opler M; Mors O; Correll CU; Østergaard SD
J Psychopharmacol; 2021 Sep; 35(9):1081-1090. PubMed ID: 33779360
[TBL] [Abstract][Full Text] [Related]
22. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.
Edgar CJ; Blaettler T; Bugarski-Kirola D; Le Scouiller S; Garibaldi GM; Marder SR
Psychiatry Res; 2014 Aug; 218(1-2):219-24. PubMed ID: 24809242
[TBL] [Abstract][Full Text] [Related]
23. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
24. An early improvement in depressive symptoms predicts symptomatic remission of schizophrenia treated with quetiapine: a multicenter, 4-week case-control study.
Chou YH; Chiu NM; Yang TT; Feng J; Chan CC; Lee HK;
Int Clin Psychopharmacol; 2013 Sep; 28(5):255-60. PubMed ID: 23820333
[TBL] [Abstract][Full Text] [Related]
25. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
26. Equipercentile linking of the BPRS and the PANSS.
Leucht S; Rothe P; Davis JM; Engel RR
Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
[TBL] [Abstract][Full Text] [Related]
27. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
28. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
[TBL] [Abstract][Full Text] [Related]
29. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
[TBL] [Abstract][Full Text] [Related]
30. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
[TBL] [Abstract][Full Text] [Related]
31. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
Lasser RA; Bossie CA; Gharabawi GM; Kane JM
Schizophr Res; 2005 Sep; 77(2-3):215-27. PubMed ID: 15908183
[TBL] [Abstract][Full Text] [Related]
32. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
34. Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai.
Zhang HX; Shen XL; Zhou H; Yang XM; Wang HF; Jiang KD
Psychiatry Res; 2014 Jan; 215(1):20-5. PubMed ID: 24230993
[TBL] [Abstract][Full Text] [Related]
35. Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.
Pinna F; Tusconi M; Bosia M; Cavallaro R; Carpiniello B;
BMC Psychiatry; 2013 Sep; 13():235. PubMed ID: 24294839
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia.
Allen MH; Citrome L; Pikalov A; Hsu J; Loebel A
Gen Hosp Psychiatry; 2017 Jul; 47():75-82. PubMed ID: 28807142
[TBL] [Abstract][Full Text] [Related]
37. Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients.
Misiak B; Frydecka D; Beszłej JA; Moustafa AA; Tybura P; Kucharska-Mazur J; Samochowiec A; Bieńkowski P; Samochowiec J
Int Clin Psychopharmacol; 2016 Jul; 31(4):185-91. PubMed ID: 26836264
[TBL] [Abstract][Full Text] [Related]
38. Obtaining employment as an anchor for estimating the minimum clinically important difference on the Positive and Negative Syndrome Scale (PANSS) in schizophrenia.
Leddy-Stacy MA; Rosenheck R
Psychiatry Res; 2016 Apr; 238():304-309. PubMed ID: 27086249
[TBL] [Abstract][Full Text] [Related]
39. One-year functional outcomes of naturalistically treated patients with schizophrenia.
Spellmann I; Riedel M; Schennach R; Seemüller F; Obermeier M; Musil R; Jäger M; Schmauß M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ
Psychiatry Res; 2012 Aug; 198(3):378-85. PubMed ID: 22421065
[TBL] [Abstract][Full Text] [Related]
40. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
Loebel A; Silva R; Goldman R; Watabe K; Cucchiaro J; Citrome L; Kane JM
J Clin Psychiatry; 2016 Dec; 77(12):1672-1680. PubMed ID: 27454547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
